No Carolina / NY / Florida
Ph: 561.316.3330

No Carolina | NY | Florida

Aidoc Delivers the Most Comprehensive Neuroscience Package for AI-driven Coordination with New FDA 510(k) Clearance for Brain Aneurysm

End-to-end care coordination workflows tailored to radiologists, neuroendovascular surgeons and neurologists

Editor: What To Know

  • The brain aneurysm solution delivers a care coordination workflow that is tailored to radiologists, neuroendovascular surgeons and neurologists, who need to treat multiple and different types of patients, whether from the emergency room, outpatients, at the hub, or transfered from the spoke.
  • Aidoc's AI platform enables seamless addition of new AI solutions as a native part of the workflow, eliminating the need to train current and new personnel as additional solutions are adopted by the hospital.
  • “We're excited to include this algorithm in our set of neuro solutions, addressing the challenge of providing timely and accurate notifications of brain aneurysm cases.

Aidoc, the leading provider of healthcare AI solutions, announced today that it received its 9th FDA 510(k) clearance for triage and notification of brain aneurysm. This announcement further strengthens Aidoc’s position as the leading provider of the most comprehensive, enterprise-grade clinical AI platform, including the broadest neuroscience suite offered to clinicians around the world.

One out of 50 people suffer from a brain aneurysm in the U.S. each year. Overlooked 10 percent of the time, incidental positive cases often go unnoticed due to their small size and complexity of blood vessels in the brain. If ruptured, patients face a 50 percent chance of fatality. Adding to its repertoire of neuro solutions that include LVO (M1), ICH and C-spine fractures, Aidoc’s newly FDA-cleared solution now flags and communicates suspected positive cases of brain aneurysm.

The brain aneurysm solution delivers a care coordination workflow that is tailored to radiologists, neuroendovascular surgeons and neurologists, who need to treat multiple and different types of patients, whether from the emergency room, outpatients, at the hub, or transfered from the spoke.

“In the U.S., there is, tragically, a brain aneurysm rupture every 18 minutes. It’s an acute condition that can quickly turn fatal, so time is of the essence, especially for late night reading,” said Elad Walach, Co-founder and CEO of Aidoc. “We’re excited to include this algorithm in our set of neuro solutions, addressing the challenge of providing timely and accurate notifications of brain aneurysm cases. With this 9th FDA clearance in three years, we stay committed to providing the most comprehensive platform in the space.”

Aidoc’s AI platform enables seamless addition of new AI solutions as a native part of the workflow, eliminating the need to train current and new personnel as additional solutions are adopted by the hospital.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Recent News

CV Societies Propel Plans Forward for a New Board of Cardiovascular Medicine

“The open comment period is the time for cardiovascular physicians, allies in other medical specialties, patients, and others to make their voices heard on why an independent CV Board is the best path for cardiologists to stay up-to-date on best practices and evidence-based care, ensuring patients receive the best possible care,” said Jeffrey Kuvin, MD, president of the proposed Board’s new Board of Directors. “The field of cardiovascular medicine has evolved dramatically over the past few decades; now is the right time to develop an independent cardiovascular Board.”

Hyundai Bioscience Announces Clinical Development Plan for Niclosamide-based Metabolic Anticancer Drug Targeting P53 Mutation Cancer

Sang-ki Oh, CEO of Hyundai Bioscience, stated, "Niclosamide-based metabolic anticancer drug candidate will be the first P53-targeting anticancer treatment that selectively kills p53 mutated cancer cells," and added, "Through our subsidiary ADM Korea, we plan to conduct clinical trials targeting cancer patients with intractable cancer caused by p53 mutations, which will be the first step of clinical development on niclosamide-based anticancer agent pipeline."

Sedana Medical Completes Patient Recruitment for INSPiRE-ICU 1 Clinical Trial in the US

Peter Sackey further elaborated: "Once the 30-day follow-up of all patients is complete, we will enter into an intense phase of final monitoring, data cleaning and transfer to our statistician team for analysis. In parallel, the long-term outcomes at 3 and 6 months will be collected centrally by the Critical Illness, Brain Dysfunction, and Survivorship team at Vanderbilt Medical Center. With this parallel approach, we expect topline results in the autumn of this year and a swift regulatory submission in Q1, 2025".

Health / Lifestyle

Articles of Interest

Stay Connected

spot_img

About Medical Device News Magazine

About Medical Device News Magazine. A digital publication founded in 2008 located in the United States. The publication is one of the industry’s leading sources of medical device and biotech industry updates. Medical Device News Magazine is easily accessible 24/7/365 and is a fast 1, 2, 3 easy read! Our purpose is...

By using this website you agree to accept Medical Device News Magazine Privacy Policy